Latest Conference Articles

Sevabertinib demonstrated high and durable objective response rates in pretreated and treatment-naive HER2-mutant NSCLC, with a manageable safety profile.

A randomized phase 2 study of a GSK-3ß inhibitor plus gemcitabine/nab-paclitaxel showed survival benefit in patients with untreated metastatic pancreatic ductal adenocarcinoma.

An updated 4-year analysis indicates nivolumab/relatlimab offers comparable PFS and OS to nivolumab/ipilimumab in advanced melanoma, with lower toxicity.

Amivantamab plus chemotherapy significantly improved PFS and ORR in EGFR-mutated NSCLC patients resistant to osimertinib, regardless of resistance mechanisms.

Luspatercept significantly improved red blood cell transfusion independence duration and overall survival in ESA-naive, lower-risk MDS patients vs epoetin alfa.

Adagrasib plus pembrolizumab improved efficacy in KRAS G12C-mutant NSCLC, according to data from the KRYSTAL-7 trial.

Dose adjustments enabled longer NALIRIFOX exposure and survival in select metastatic PDAC patients, with favorable clinical profiles despite multiple metastatic sites.

Fruquintinib plus camrelizumab, paclitaxel liposome, and nedaplatin showed a 68.4% ORR and acceptable safety in advanced ESCC.

At ASCO 2025, Suneel Kamath, MD, presented an analysis of federal cancer research funding disparities and their ripple effects on care delivery and outcomes.

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– breast cancer in the SERENA-6 trial.

Neoadjuvant PAXG led to a significant improvement in event-free survival vs mFOLFIRINOX in resectable or borderline resectable pancreatic ductal adenocarcinoma.

Adjuvant nivolumab offered sustained survival benefits in resected esophageal/GEJ cancer post chemoradiation, with PD-L1 emerging as a potential biomarker.

Nivolumab with cisplatin and radiotherapy improved disease-free survival in high-risk locally advanced squamous cell carcinoma of the head and neck in the NIVOPOSTOP trial.

Durvalumab plus FLOT improved event-free survival vs placebo in resectable gastric/GEJ cancer.

In the phase 3 PANOVA-3 trial, patients who underwent tumor-treating fields therapy had extended overall survival vs standard-of-care gemcitabine plus nab-paclitaxel.

A 3-year structured exercise program significantly improved DFS and OS in stage II/III CRC, reducing recurrence by 28% and death risk by 37%.

Less inflammatory diets were linked to improved overall survival in stage III colon cancer, and physical activity showed synergistic benefits.

Erin Cobain, MD, discusses findings from a study exploring the differences in diagnosis and treatment of high-risk breast cancer in Black and White patients.

The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations for advanced colorectal cancer.

Naomi Haas, MD, discusses the 5-year follow-up of the KEYNOTE-564 study being presented at the 2025 ASCO Annual Meeting.

DNA methylation, RTK pathway changes, and KRAS amplifications may drive resistance to sotorasib plus panitumumab in KRAS G12C colorectal cancer.

Escalated adjuvant chemotherapy, guided by ctDNA, did not improve recurrence-free survival for stage III colon cancer patients, per DYNAMIC-III trial.

Sara M. Tolaney, MD, MPH, shares new data from the ASCENT-04 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer.

Nivolumab plus ipilimumab shows durable survival benefit over chemotherapy and monotherapy in mismatch repair-deficient colorectal cancer.

Anlotinib plus chemotherapy has emerged as a first-line alternative to bevacizumab/chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer.

The BREAKWATER trial showed encorafenib, cetuximab, & mFOLFOX6 significantly improved PFS and OS in first-line BRAF V600E-mutant mCRC.

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy, improving survival without disease progression.

Vepdegestrant significantly improved progression-free survival vs fulvestrant in pretreated ESR1-mutant, ER-positiver, HER2-negative advanced breast cancer.